gene therapy – Medxy AI

Treatment Evolution in 5q-Spinal Muscular Atrophy: Real-World Evidence and Clinical Insights from the SMArtCARE Registry

By MedXY 03/08/2026

This review analyzes the shifting landscape of SMA therapy using data from 2,140 patients, highlighting the transition between nusinersen, risdiplam, and onasemnogene abeparvovec and the factors driving treatment switches.

Neurology news Pediatrics

Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial

By MedXY 03/08/2026

The Phase 3 CIFFREO trial found that the gene therapy fordadistrogene movaparvovec did not significantly improve motor function in boys with Duchenne muscular dystrophy compared to placebo, leading to the discontinuation of its clinical development due to a negative benefit-risk profile.

Neurology news Pediatrics

CIFFREO Trial Results: Fordadistrogene Movaparvovec Fails Primary Efficacy Endpoint in Duchenne Muscular Dystrophy

By MedXY 02/24/2026

The Phase 3 CIFFREO trial for the gene therapy fordadistrogene movaparvovec failed to meet its primary efficacy endpoint in boys with Duchenne muscular dystrophy, showing no significant functional improvement over placebo and leading to the discontinuation of its clinical development.

Neurology news Pediatrics

AAV9 Gene Therapy Shows Clinical Promise in Stabilizing Type II GM1 Gangliosidosis

By MedXY 02/23/2026

A Phase 1-2 trial of AAV9-GLB1 gene therapy in children with Type II GM1 gangliosidosis demonstrates significant biochemical improvements and stabilization of neurodevelopmental decline, marking a pivotal step toward treating this fatal lysosomal storage disorder.

Hematology-Oncology Nephrology news

Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

By MedXY 02/22/2026

A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.

Cardiology General Surgery news

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

By MedXY 02/04/2026

The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeutic breakthrough for an underserved patient population.

Hematology-Oncology news Pediatrics

Beyond the CNS and Skeleton: HSPC-Gene Therapy (OTL-203) Demonstrates Superior Multi-System Efficacy in Hurler Syndrome

By MedXY 01/20/2026

A clinical study comparing OTL-203 gene therapy to allogeneic HSCT for Hurler syndrome reveals significant improvements in corneal clarity, hearing preservation, and cardiac stability, marking a potential shift in the standard of care for multisystemic lysosomal storage disorders.

Dermatology news Pediatrics

Breaking the Cycle of Chronic Wounds: Prademagene Zamikeracel Sets New Standard for RDEB Treatment

By MedXY 01/07/2026

The Phase 3 VIITAL trial demonstrates that prademagene zamikeracel, an autologous gene-modified cellular sheet, significantly improves healing and reduces pain in patients with recessive dystrophic epidermolysis bullosa (RDEB), offering a transformative approach to managing large, chronic wounds.

Hematology-Oncology Internal Medicine news

Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B

By MedXY 12/19/2025

The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine prophylaxis in the vast majority of participants.

Hematology-Oncology news

Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes

By MedXY 11/11/2025

The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acceptable short‑term safety profile and no genotoxicity detected during follow‑up.

news Otorhinolaryngology Pediatrics

AAV‑OTOF Gene Therapy Restores Substantial Hearing in DFNB9 Across Ages — Rapid, Age‑dependent Benefits in a First-in‑Human Trial

By MedXY 11/04/2025

A single‑arm trial of AAV‑OTOF (Anc80L65) in 10 patients (1.5–23.9 years) with autosomal recessive deafness 9 showed good tolerability and rapid, clinically meaningful hearing gains, with optimal outcomes in children aged 5–8 years; longer follow‑up is required.

news Otorhinolaryngology Pediatrics

OTOF Gene Therapy Rivaled—and in Some Domains Outperformed—Cochlear Implants in Restoring Hearing and Speech in Congenital Deafness

By MedXY 11/04/2025

A 2022–2024 nonblinded cohort study found OTOF gene therapy produced rapid, durable gains in auditory thresholds, speech perception, mismatch-negativity responses, and music perception versus cochlear implantation in children with genetically driven congenital deafness.

news Otorhinolaryngology Pediatrics

DB-OTO Restores and Sustains Hearing in Otoferlin-Deficient Mice: A Hair-Cell–Targeted Dual-AAV Strategy Advances to Clinical Testing

By MedXY 11/04/2025

DB-OTO, a hair-cell-specific dual-AAV gene therapy encoding full-length human otoferlin, achieved dose-dependent and sustained auditory restoration in OTOF-deficient mice, supporting an ongoing Phase I/II pediatric trial.

Allergy & Immunology Hematology-Oncology news

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

By MedXY 10/25/2025

This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.

news Otorhinolaryngology Pediatrics

DB-OTO Gene Therapy: A Breakthrough Treatment for OTOF-Related Inherited Deafness in Children

By MedXY 10/24/2025

Regeneron's DB-OTO gene therapy shows promising results in restoring natural hearing in children with profound hearing loss caused by OTOF gene mutations, with 75% achieving significant hearing improvement after a single treatment.

Hematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY 10/24/2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

Allergy & Immunology Clinical Updates Dermatology Pediatrics Specialties

Prademagene Zamikeracel: A Breakthrough Gene Therapy for Chronic Wounds in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

By MedXY 08/02/2025

A phase 3 trial demonstrates prademagene zamikeracel significantly accelerates healing and reduces pain in large, chronic RDEB wounds, offering a promising gene therapy with a favorable safety profile.

Clinical Updates Hematology-Oncology news Specialties

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

By MedXY 08/02/2025

Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.

Clinical Updates Hematology-Oncology news Specialties

Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results

By MedXY 08/01/2025

A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.